In a clinical trial directly comparing sustained release formulations of pasireotide and octreotide in a large cohort of randomly allocated, medically naive patients with acromegaly, pasireotide was found to control GH and IGF-1 in a greater percentage (31.3% pasireotide treatment versus 19.2% octreotide treatment) of subjects (Colao et al., 2014). Here, IGF1 is linked to acromegaly.